The 2016 World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (MPN) underscore the prognostically-relevant distinction between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF). In addition, leukocytosis has been identified as an important prognostic marker in otherwise WHO-defined ET. However, controversy remains regarding the objectivity of morphologic criteria in distinguishing ET from pre-PMF and the precise prognostic cutoff values for leukocytosis. Serum lactate dehydrogenase (LDH) level might be a biologically more accurate measure of leukocyte turnover and a more sensitive marker of pre-PMF, in otherwise WHO-defined ET. In the current study of 183 consecutive patients with WHO-defined ET, the presence of grade 1 bone marrow (BM) fibrosis did not affect presenting clinical or laboratory features; in contrast, increased serum LDH at diagnosis was associated with leukocytosis (p 5 .002), thrombocytosis (p < .001), palpable splenomegaly (p 5 .03) and higher international prognostic score (IPSET) (p 5 .002); serum LDH did not correlate with BM fibrosis, JAK2/CALR/ MPL or TET2/ASXL1 mutations. In univariate analysis, risk factors for survival included age 60 years (p 5 .002; HR 10.2, 95% CI 2.3-44.6), male sex (p 5 .02; HR 3.2, 95% CI 1.2-8.2), leukocyte count 15 3 10 9 /L (p 5 .007; HR 4.7, 95% CI 1.5-14.6), and increased serum LDH (p 5 .002; HR 3.7, 95% CI 1.5-9.1), but not BM fibrosis (p 5 .17). In multivariable analysis, age, sex and serum LDH remained significant; serum LDH also remained significant, in the context of IPSET (p 5 .003) and in patients with leukocytosis (p 5 .003). We conclude that serum LDH level carries an independent prognostic value for survival in ET and might represent a biologically more accurate surrogate for leukocytosis.
| I N T R O D U C T I O N
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by proliferation of enlarged and mature megakaryocytes, without significant abnormalities in granulopoiesis or erythropoiesis. 1 The 2016 World Health Organization (WHO) diagnostic criteria for ET include platelet count of 450 3 10 9 /L, demonstration of JAK2, MPL, or CALR mutations, and exclusion of other myeloid neoplasms and causes of reactive thrombocytosis. 1 The distribution of JAK2, CALR, and MPL mutations in ET are 55, 25, and 3%, respectively; approximately 17% are triple-negative. 2 Clinical course of patients with ET may be complicated by arterial or venous thrombosis and, in the long term by fibrotic and leukemic transformations. 3 ET shares certain bone marrow histological, clinical phenotype, and molecular markers, with early/prefibrotic primary myelofibrosis (pre-PMF). 2, 4 In a landmark study of 1104 patients with presumed ET, the International Working Group for MPN Research and Treatment (IWG-MRT) identified 180 (16%) patients in whom the diagnosis was revised into pre-PMF, after a central pathologic review. 5 More importantly, the study showed significantly worse overall (OS), leukemia-free (LFS) and myelofibrosis-free (MFFS) survival in patients with pre-PMF, compared to those with WHO-defined ET. 5 This prognostically-relevant distinction between pre-PMF and ET has since been endorsed by both the 2008 and 2016 WHO documents. 1, 6 In a subsequent study of the 891 patients with WHO-defined ET, the IWG-MRT identified advanced age (60 years), leukocytosis (11 3 10 9 /L) and history of thrombosis as risk factors for inferior survival.
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The above-mentioned two IWG-MRT studies have established the prognostic importance of prefibrotic morphology and leukocytosis in ET. However, controversy remains regarding the objectivity of megakaryocyte morphology in distinguishing ET from pre-PMF 5, [8] [9] [10] [11] [12] [13] [14] and the precise cutoff values for leukocytosis. 5, 11, 15, 16 Accordingly, we hypothesized that serum LDH level might be a biologically more accurate measure of leukocyte turnover as well as a more sensitive marker of pre-PMF, and therefore explored its independent prognostic relevance in the current study.
| M E T H O D S
The current study was approved by the institutional review board of 
| DISCUSSION
The key finding in the current study was the identification of serum LDH as an independent prognostic factor in WHO-defined ET. Prior studies have shown that serum LDH may be increased in ET, [20] [21] [22] [23] [24] but none have systematically evaluated its prognostic impact. This is a practically appealing observation because the particular laboratory test is widely available and inexpensive. The current study also suggested that serum LDH might supersede leukocyte count in its prognostic value and this might be related to its property as a biologically more accurate measure of cell turnover; in the current study, serum LDH was the only independent risk factor for survival, other than age and sex, and its prognostic effect was shown to be independent of leukocyte count and most apparent in patients with leukocytosis. It is also possible that increased serum LDH is a more sensitive marker of occult pre-PMF. Consistent with the latter contention, a study from the IWG-MRT that included 536 patients in the test cohort and 321 patients in a validation cohort examined the discriminatory power of several laboratory parameters, including serum LDH, and found the latter to have the best performance in distinguishing pre-PMF from WHO-defined ET. 25 The observations in the current study carry the potential to significantly affect current models of prognostication in ET and possibly other MPN. At present, risk stratification for survival in ET is according [27] [28] [29] [30] Unlike the case with serum LDH, and mostly consistent with previous observations, 31,32 the presence of mild BM reticulin fibrosis was of limited value in predicting survival in the current study. This observation is similar to polycythemia vera (PV) studies performed by our group and the IWG-MRT, in which mild BM fibrosis has no impact on OS. 28, 30 Previous reports have shown that reticulin grade at diagnosis was correlated with increased leukocyte count, platelet count, arterial thrombosis, major hemorrhage and higher risk of fibrotic transformation. 31, 32 These observations were not reproduced in the current study but this might be related to the small sample size, especially in terms of informative cases. Serum LDH was not fractionated into isoenzymes for the current study. However, a prior study has shown increased LDH3 in ET patients suggesting the value of LDH isoenzyme fractionation. 20 Regardless, the systematic inclusion of serum LDH in future studies should help clarify not only its independent prognostic role but also its prognostic interaction with bone marrow fibrosis. 
